BFRI biofrontera-us.com: מקדם חוב לטווח ארוך להון

Biofrontera Inc. has reached a stage of maturity by developing current keratosis therapy methods and expanding insurance limits. This price action on GURU.Markets with the 1.23 metric highlights the market power of a business that profits from high-margin exclusive skin treatment equipment. Stable demand for prescription drugs provides the assets with defensive qualities and ensures revenue resilience regardless of economic phases.

The "razor-and-blade" model of Biofrontera Inc. (BFRI) ensures a steady cash flow through recurring gel sales. Analyzing the share of long-term loans in equity allows for an assessment of the sustainability of this scaling strategy. The current value of 1.23 reflects the ratio of liabilities with a maturity of over one year to the market value of assets. A decrease in this coefficient minimizes financial risks but may signal a slowdown in expansion. The asset is categorized as a high-risk biopharmaceutical security.